Uses
LASTACAFT ® is an H 1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.
Source: US FDA prescribing information
Alcaftadine is a histamine-1 receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. It is available as eye drops for ophthalmic use. MedsAcross supplies Alcaftadine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LASTACAFT ® is an H 1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.
Source: US FDA prescribing information
Alcaftadine is an H 1 histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.
Source: US FDA prescribing information
Instill one drop in each eye once daily. If more than 1 topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart.
Source: US FDA prescribing information
LASTACAFT ® is contraindicated in patients with hypersensitivity to any component in the product. Hypersensitivity
Source: US FDA prescribing information
• Potential for Eye Injury and Contamination: To minimize the risk of eye injury and contamination, do not touch dropper tip to eyelids and surrounding areas, or any other surface. Keep bottle tightly closed when not in use. • Contact Lens Wear: LASTACAFT ® should not be used to treat contact lens-related irritation. Remove contact lenses prior to instillation of LASTACAFT ®.
Source: US FDA prescribing information
The most common ocular adverse reactions, occurring in less than 4% of eyes treated with LASTACAFT ®, were eye irritation, burning and/or stinging on instillation, eye redness, and eye pruritus.
Source: US FDA prescribing information
Store at 15°C to 25°C (59°F to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Alcaftadine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Lastacaft 2.5 mg/mL eye dropsOphthalmic | Allergan | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 28 July 2010 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Alcaftadine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Alcaftadine, including Lastacaft.
Yes. The US FDA first approved Alcaftadine on 28 July 2010, according to Drugs@FDA.
No listed presentation of Alcaftadine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Alcaftadine is classified under ATC code S01GX11 (Alcaftadine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.